Paradigm Peptides Alternatives: Choosing a Supplier After a Fully Adjudicated Case | Artemis Labs
Paradigm Peptides Alternatives: What a Fully Adjudicated Case Teaches About Vendor Selection
Published August 21, 2026 · Artemis Labs
Paradigm Peptides alternatives should be judged against what the court record established: products labeled as SARMs contained testosterone, and owner Matthew Kawa pleaded guilty to introducing unapproved drugs into interstate commerce with intent to defraud and mislead. The successor question is therefore an identity question — does the vendor prove, by mass spectrometry, that the vial matches the label?
Key findings
- Fully adjudicated. Unlike most vendor shutdowns in this market, the Paradigm Peptides case ran to completion: guilty pleas on December 10, 2025 and sentencing on July 30, 2026 in the Northern District of Indiana — the record is court-established, not rumor.
- Labeled one thing, contained another. Per the court record, Paradigm Peptides products labeled as SARMs contained testosterone, a Schedule III substance — precisely the failure that third-party mass-spectrometry identity testing exists to catch.
- The brand outlived the company. Paradigm Peptides’ site went down in March 2024, yet a similarly named domain, paradigmpeptides.is, later appeared — itself stating it has no affiliation — which is why any defunct vendor’s brand warrants a lookalike-domain check.
The case, dated
Paradigm Peptides’ website went down in March 2024. On December 10, 2025, owner Matthew Kawa, 48, pleaded guilty to introducing unapproved drugs into interstate commerce with intent to defraud and mislead, and to illegally importing merchandise; Jennifer Stechkober, 32, his sister and the company’s main employee, also pleaded guilty. On July 30, 2026, a federal court in South Bend (Northern District of Indiana) sentenced Kawa to 70 months, one year of supervised release, and $5 million in forfeiture, and Stechkober to 16 months. The products at issue included peptides, hCG, and SARMs. The CBS News report and the U.S. Attorney’s Office record are cited in the References.
For a researcher, the significance of Paradigm Peptides is not the sentence — it is that this is the research-peptide market’s fully adjudicated case. Warning letters allege; raids interrupt; a guilty plea establishes facts. What those established facts say about the products is the part worth studying.
What the record shows: the label and the vial did not match
Per the court record, Paradigm Peptides products labeled as SARMs contained testosterone, a Schedule III substance. Set the legal weight of that finding aside for a moment and read it as a data-integrity problem: a buyer who ran experiments with that material was generating observations about a compound they did not know they had. Every measurement, every comparison against the literature, every conclusion — attached to the wrong molecule.
Purity numbers do not defend against this. A vial can be highly pure and still hold the wrong substance. The failure mode the Paradigm Peptides record documents is an identity failure, and identity is a specific, testable property — which points directly at the successor criteria below.
Mass spectrometry is the test built to catch this
Third-party identity verification by mass spectrometry answers one question: is the molecule in the vial the molecule on the label? HPLC answers a different one: how much of the sample is the main component? A Certificate of Analysis that shows only a purity percentage can look reassuring while never establishing identity at all — which is the exact gap the Paradigm Peptides record fell through. Our guide to reading a Certificate of Analysis shows where identity data appears on a real COA and what its absence looks like, and our supplier-evaluation framework ranks identity evidence above every other criterion for exactly this reason.
Check for lookalike domains before entering payment details
Paradigm Peptides’ original site went down in March 2024. A similarly named domain — paradigmpeptides.is — later appeared, itself stating that it has no affiliation with the original company. The pattern is not unique to Paradigm Peptides: when Peptide Sciences closed in March 2026, its own closure notice stated that any further sales under its brand are fraudulent, and unaffiliated sites reusing that branding have appeared since. A defunct vendor’s brand keeps its search demand long after it loses its owner, and that demand attracts registrants. Before paying anyone trading under a dead vendor’s name, assume no continuity with the original unless independently proven.
Successor criteria, and how Artemis Labs answers them
The Paradigm Peptides record reduces vendor selection to one sharp question: what evidence does this supplier give that its labels are true? Concretely, a successor should show a third-party COA with every order pairing MS identity with HPLC purity; product pages that cite primary literature, not outcome language; no administration supplies or dosing content anywhere; and published shipping, refund, privacy, and research-use terms. The same framework applied to the raid tier of enforcement is in our Amino Asylum alternatives article, and the market-wide picture is on the 2025–2026 peptide vendor closures hub.
Against those criteria, Artemis Labs states only what is factual. Every order ships with a third-party Certificate of Analysis covering MS identity verification and HPLC purity. Roughly 500 PubMed and DOI citations run across the catalog, with a References section on every product page. Unfavorable findings are disclosed — the 2025 Sun result on Tβ4 appears on the relevant product page. No administration supplies are sold and no dosing content is published anywhere, and the shipping, refund, privacy and research-use terms are public — the terms of sale make research use a condition of the sale, not a line of small print. Compounds in the Artemis Labs catalog are supplied for laboratory research use only.
Frequently asked questions
Who pleaded guilty in the Paradigm Peptides case?
Matthew Kawa, 48, the owner, pleaded guilty to introducing unapproved drugs into interstate commerce with intent to defraud and mislead and to illegally importing merchandise; Jennifer Stechkober, 32, his sister and the company’s main employee, also pleaded guilty. Both pleas were entered on December 10, 2025.
What sentences did the Paradigm Peptides defendants receive?
Kawa received 70 months, one year of supervised release, and a $5 million forfeiture; Stechkober received 16 months. Sentencing took place on July 30, 2026, in South Bend, in the Northern District of Indiana.
Is paradigmpeptides.is connected to the original Paradigm Peptides?
The site itself states it has no affiliation with the original company. Given that the original Paradigm Peptides site went down in March 2024 and its owner was later sentenced, any domain trading on the name deserves the same skepticism as any unverified vendor: start from zero and require current, third-party documentation.
How is the Paradigm Peptides case different from the Amino Asylum raid?
Paradigm Peptides is fully adjudicated — guilty pleas in December 2025, sentencing in July 2026 — while the verified Amino Asylum record ends at the June 2025 raid, with no court outcome documented. Secondary coverage frequently blends the two; the pleas and sentences belong to Paradigm Peptides alone.
References
- CBS News — peptides seller receives prison sentence over unapproved drugs (primary-verified report on the Paradigm Peptides case)
- U.S. Attorney’s Office, Northern District of Indiana — sentencing record, July 30, 2026 (South Bend).
